Loading
A phase 3 trial of Penpulimab, Cisplatin, Carboplatin in nasopharyngeal carcinoma, run by Akeso, active and no longer recruiting.
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT04974398 by Akeso, with 296 participants enrolled, started 2021-08-16 and due to reach its primary completion in 2026-02-23. Interventions recorded: Penpulimab, placebo. Conditions listed: Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Shares Akeso, Gemcitabine, Cisplatin, Carboplatin.
Shares Penpulimab, Gemcitabine, Immune checkpoint inhibitors.
Shares Akeso, Gemcitabine, Cisplatin, Immune checkpoint inhibitors.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Gemcitabine, Immune checkpoint inhibitors.
Shares Penpulimab, Gemcitabine, Cisplatin, Carboplatin.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Gemcitabine.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma, Cisplatin, Immune checkpoint inhibitors.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma.